Florin Draica of Shionogi explains the 72-hour PEP window for ensitrelvir, breakthrough infection data, and which patients to ...
CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic ...
Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.
Infectious disease and urology clinicians described unclear treatment goals, infusion limits, and access barriers for newer ...
New ACACIA-HCM analyses at HCMS 2026 add imaging and quality-of-life data as Cytokinetics readies an FDA filing in nonobstructive HCM.
An oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer.
Prerna Mewawalla, MD, discusses fixed-duration bispecifics to limit infection risk and real-world data showing poor outcomes ...
New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.
San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.
Cardiologists and pharmacy leaders explained how team-based clinics and standardized paperwork are speeding obstructive HCM ...
The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.